Early Cenobamate as a Third-Line Option in Drug-Resistant Focal Epilepsy: A Paradigm Shift? - PubMed
6 hours ago
- #Third-Line Therapy
- #Drug-Resistant Epilepsy
- #Cenobamate
- Cenobamate (CNB) as an early third-line therapy shows a 94.1% 12-month retention rate in drug-resistant focal epilepsy (DRE).
- CNB demonstrated higher seizure freedom rates (62.5%) compared to perampanel (43.7%) and brivaracetam (16.6%) at 12 months.
- Adverse events were less frequent with CNB (9.4%) than with other third-line ASMs (35.3%) and were generally non-treatment-limiting.
- Generalized linear mixed-effects models (GLMMs) confirmed a significant reduction in seizure frequency over time for CNB patients.
- The study suggests CNB has favorable effectiveness and tolerability, supporting further research into optimal treatment sequencing for DRE.